参麦注射液联合R-CHOP治疗对弥漫大B细胞淋巴瘤疗效及免疫功能的影响  

作　　者：王晓霞[1] 吴功强[1] 吴洵民 卢参参 

机构地区：[1]温州医科大学附属东阳医院血液科,322100

出　　处：《浙江临床医学》2017年第8期1387-1389,共3页Zhejiang Clinical Medical Journal

基　　金：浙江省金华市市级重点科研项目（2016-3-014）;浙江省医学会临床科研基金项目（2011ZYC-A71）

摘　　要：目的 观察参麦注射液联合R-CHOP对弥漫大B细胞淋巴瘤患者疗效及免疫功能的影响.方法 采用随机对照研究方法,将弥漫大B细胞淋巴瘤初治患者81例,分为观察组（n=42）和对照组（n=39）.观察组给予R-CHOP21方案化疗加参麦注射液治疗;对照组单用R-CHOP21方案化疗.比较两组患者化疗前后外周血淋巴细胞亚群的变化,并对两组疗效及不良反应进行评价.结果 观察组和对照组有效率分别为92.8%和87.2%,差异无统计学意义（P〉0.05）.观察组不良反应发生率明显低于对照组,差异具有统计学意义（P=0.001）.观察组化疗后CD3^＋、CD4^＋、NK细胞水平显著高于化疗前和对照组化疗后水平（P〈0.05）,CD4^＋/CD8＋比值较化疗前及对照组化疗后明显上升（P〈0.05）.对照组化疗后CD3^＋、CD4^＋、NK细胞水平及CD4^＋/CD8＋比值与化疗前比较差异无统计学意义（P〉0.05）.结论 虽然参麦注射液对弥漫大B细胞淋巴瘤患者疗效方面未体现优势.但该药能显著提高化疗期间的细胞免疫功能,而且降低化疗不良反应,从而提高患者生存质量.Objective To investigate the effect of efficacy and immune function of Shen Mai injection combined with R-CHOP chemotherapy in treatment of diffuse large B cell lymphoma. Methods Eighty-one patients of diffuse large B cell lymphoma were randomly divided into treatment group （n=42）and control group（n=39）. The treatment group was treated with R-CHOP21 chemotherapy plus Shen Mai injection,and the control group was treated with R-CHOP21 regimen alone. The changes of peripheral blood lymphocyte subsets were compared between the two groups before and after chemotherapy,and the efficacy and adverse reactions of the two groups were evaluated. Results The efficiency rate of treatment group and control group were 92.8% and 87.2%,respectively,with no significant difference（P〉0.05）. The incidence of adverse reactions in the treatment group was significantly lower than that in the control group,the difference was statistically significant（P=0.001）. The levels of CD3^＋,CD4^＋ and NK cells in the treatment group were significantly higher than those before chemotherapy and after chemotherapy of the control group（P〈0.05）,the ratio of CD4^＋/CD8＋ was significantly higher than that before chemotherapy and after chemotherapy of the control group（P〈0.05）. There was no significant difference in the control group on CD3^＋,CD4^＋,NK cell levels and CD4^＋/CD8＋ ratio before and after chemotherapy（P〉0.05）. Conclusion Although the therapeutic effect of Shen Mai on diffuse large B cell lymphoma patients don＆#39;t reflect the advantages. But the drug can significantly improve the cellular immune function during chemotherapy,and reduce adverse drug reaction,thus improving the quality of life of patients.

关 键 词：弥漫性大B细胞淋巴瘤 参麦注射液 效率 不良反应率 免疫功能 

分 类 号：R733[医药卫生—肿瘤]